Overview of postmarketing experience with ofloxacin in Germany

Area of Science:

• Pharmacovigilance
• Clinical Pharmacology

Background:

• Clinical trials for ofloxacin indicated a low incidence of mild adverse drug events (ADEs).
• Postmarketing surveillance is crucial for identifying rare adverse events not detected during clinical trials.

Purpose of the Study:

• To present the status of results from postmarketing surveillance of ofloxacin.
• To evaluate the safety profile of ofloxacin after its market launch.

Main Methods:

• Analysis of 985 spontaneous national reports of ADEs over 2.5 years post-ofloxacin launch in Germany.
• Calculation based on approximately 3.5 million patients treated with a mean daily dose of 400 mg for seven days.

Main Results:

• Rare adverse events, including hallucination, psychotic reaction, and shock, were reported.
• These rare events were not observed in pre-marketing clinical trials.
• The overall risk:benefit ratio of ofloxacin remained favorable.

Conclusions:

• Postmarketing surveillance identified rare adverse events associated with ofloxacin.
• The favorable risk:benefit profile of ofloxacin is maintained despite the identification of rare ADEs.